Pharmafile
FEBRUARY 2, 2023
Novartis, a Swiss pharmaceutical company, has announced in its 2022 full-year report that it is cutting several of their programmes, including their Huntington’s disease trial.
Fierce Pharma
FEBRUARY 2, 2023
Novo's Rybelsus comes into its own as Wegovy shakes off supply constraints fkansteiner Thu, 02/02/2023 - 08:57
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmafile
FEBRUARY 3, 2023
French clinical-stage biotech company Genoscience has received FDA Orphan Drug Designation (ODD) for its lead candidate ezurpimtrostat. OOD qualifies the drug for a potential of seven years of market exclusivity after approval. Hepatocellular carcinoma (HCC) is a largely fatal cancer, with the median survival time for patients being between four and eight months.
Drug Topics
FEBRUARY 1, 2023
Geographical data could potentially yield insight on racial and ethnic health disparities in the United States. An analysis of the large dataset could help identify any potential causes for observed inequities.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
PharmaVoice
JANUARY 31, 2023
With the industry focused on cancer and COVID-19, Marc de Garidel made deals centered on cardio.
PhRMA
JANUARY 31, 2023
Middlemen don’t want patients to know how they are stacking the deck against them.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Drug Topics
JANUARY 30, 2023
As a dozen Humira Biosimilars are set to enter the market this year, it seems to be unlikely that they will drive down drug costs in the future.
PharmaVoice
JANUARY 30, 2023
Emerging channels offer new ways to reach key targets and improve campaign ROI.
PhRMA
FEBRUARY 1, 2023
January was National Glaucoma Awareness Month and provided us an opportunity to spread the word and honor the millions of patients around the world who are impacted by this debilitating disease. Glaucoma refers to a group of eye diseases that can cause vision loss or blindness due to damage of the optic nerve. It is one of the leading causes of irreversible blindness in the United States.
STAT
JANUARY 30, 2023
The federal government will audit Medicare Advantage insurers aggressively under a rule finalized Monday, which is expected to result in billions of dollars in overpayments going back toward Medicare’s trust fund and patients over the next decade. However, federal officials watered down one of the auditing policies by giving insurers seven years of immunity from having the samples of their diagnosis coding errors extrapolated to their broader Medicare Advantage membership.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Drug Topics
JANUARY 30, 2023
Pfizer Inc. and Moderna Inc. have indicated that they are going to price their shots at between $110 and $130. The shots should still be free to individuals because of rules barring out-of-pocket costs for such vaccinations.
PharmaVoice
JANUARY 30, 2023
Download the complimentary Guide to Successful Copay Programs that delivers actionable insights to pharma leaders.
PhRMA
JANUARY 31, 2023
PhRMA recently submitted comments to the Office of the U.S. Trade Representative (USTR)’s 2023 Special 301 Report. The comments highlight foreign government actions and policies that undermine American innovation, biopharmaceutical leadership and more than 4.4 million American jobs.
Fierce Pharma
FEBRUARY 3, 2023
J&J's pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries mbayer Fri, 02/03/2023 - 09:29
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Drug Topics
FEBRUARY 1, 2023
A new report unpacks some of the challenges that independent pharmacists may face in the years ahead.
PharmaVoice
JANUARY 30, 2023
Why an alliance of industry leaders is exploring the potential of social media as a treasure trove of real-world patient experience insights.
STAT
FEBRUARY 2, 2023
WASHINGTON — A majority of Americans support banning all tobacco products, according to a new poll published by researchers at the Centers for Disease Control and Prevention. The survey , which was published Thursday in the peer-reviewed journal Preventing Chronic Disease, asked 6,455 people nationwide: “To what extent would you support a policy to prohibit the sale of all tobacco products?
Fierce Pharma
JANUARY 31, 2023
Pfizer warns Comirnaty sales will plummet by nearly two-thirds in 2023.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Drug Topics
JANUARY 30, 2023
Sixteen states have banned a pharmacy benefit management practice that involves not counting the value of drug copay assistance from manufacturers toward patient deductibles.
PharmaVoice
FEBRUARY 2, 2023
The FTC and DOJ are heightening antitrust enforcement, and pharma deals are a prime target.
Fierce Healthcare
FEBRUARY 1, 2023
FTC slaps GoodRx with $1.
STAT
JANUARY 31, 2023
Stressful experiences during early childhood — particularly economic strife — appear to act as a toxic stressor that can alter regions of the brain tied to the processing of stress and trauma, according to a new study published Wednesday. The researchers found that Black children were impacted more than white children, largely because of the higher amounts of poverty and adversity they face.
Drug Topics
JANUARY 30, 2023
Elacestrant, now with the brand name Orserdu, is an oral selective estrogen receptor degrader (SERD), which works by blocking the effects of estrogen on hormone receptor-positive breast cancer cells.
PharmaVoice
FEBRUARY 2, 2023
A menagerie of earnings calls this week showed where the Big Pharma players stand in 2023.
Fierce Healthcare
JANUARY 30, 2023
White House plans to end COVID emergency declarations on May 11 hlandi Mon, 01/30/2023 - 22:10
STAT
FEBRUARY 1, 2023
Medicare Advantage insurers could face an average 2.3% cut to baseline payments in 2024, the Biden administration said Wednesday. If the proposal stands, it would be a net cut of more than $3 billion to the industry. The major reason behind the proposed pay cut: Medicare officials want to update data and coding systems that are used to explain the health conditions of an insurance company’s enrollees.
Drug Topics
FEBRUARY 3, 2023
After being FDA approved in 2021, tezepelumab (Tezspire) has been approved again for self-administration.
PharmaVoice
JANUARY 30, 2023
GLP-1 agonists are dominating the anti-obesity scene — but hurdles remain to their uptake.
Drug Store News
FEBRUARY 2, 2023
Cardinal Health’s second quarter revenue increased 13% to $51.5 billion from the prior year period.
STAT
FEBRUARY 1, 2023
Not long after the artificial intelligence company OpenAI released its ChatGPT chatbot, the application went viral. Five days after its release, it had garnered 1 million users. Since then, it has been called world-changing , a tipping point for artificial intelligence, and the beginning of a new technological revolution. Like others, we began exploring potential medical applications for ChatGPT, which was trained on more than 570 gigabytes of online textual data, extracted from sources like boo
Drug Topics
FEBRUARY 2, 2023
After an on-field cardiac arrest, Hamlin partnered with the American Heart Association to spotlight the importance of CPR
PharmaVoice
FEBRUARY 1, 2023
With positive early phase data, CEO Jill Milne is aiming to bring an improved preventative option to patients with hereditary angioedema.
Drug Store News
JANUARY 31, 2023
MedAvail has agreed to sell to CVS certain assets related to its SpotRx pharmacies located in Arizona, California, Michigan and Florida.
Expert insights. Personalized for you.
Let's personalize your content